CH619614A5 - - Google Patents

Download PDF

Info

Publication number
CH619614A5
CH619614A5 CH652476A CH652476A CH619614A5 CH 619614 A5 CH619614 A5 CH 619614A5 CH 652476 A CH652476 A CH 652476A CH 652476 A CH652476 A CH 652476A CH 619614 A5 CH619614 A5 CH 619614A5
Authority
CH
Switzerland
Prior art keywords
daunomycin
fab
tumor
drug
compounds
Prior art date
Application number
CH652476A
Other languages
German (de)
English (en)
Inventor
Michael Prof Sela
Ruth Prof Arnon
Esther Dr Hurvitz
Ruth Maron
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of CH619614A5 publication Critical patent/CH619614A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
CH652476A 1975-05-27 1976-05-24 CH619614A5 (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL47372A IL47372A (en) 1975-05-27 1975-05-27 Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same

Publications (1)

Publication Number Publication Date
CH619614A5 true CH619614A5 (is) 1980-10-15

Family

ID=11048252

Family Applications (1)

Application Number Title Priority Date Filing Date
CH652476A CH619614A5 (is) 1975-05-27 1976-05-24

Country Status (11)

Country Link
US (1) US4093607A (is)
JP (1) JPS51144723A (is)
AU (1) AU512255B2 (is)
CA (1) CA1064826A (is)
CH (1) CH619614A5 (is)
DE (1) DE2623736A1 (is)
FR (1) FR2312259A1 (is)
GB (1) GB1523980A (is)
IL (1) IL47372A (is)
SE (1) SE437767B (is)
ZA (1) ZA762966B (is)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
JPS57106625A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
DE3205847A1 (de) * 1981-05-08 1982-12-16 Farmitalia Carlo Erba S.p.A., 20159 Milano Daunorubicinprotein-konjugate
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5144011A (en) * 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
JPH06157346A (ja) * 1981-09-08 1994-06-03 Suntory Ltd 選択性制癌剤
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
JPS59134732A (ja) * 1983-01-21 1984-08-02 Green Cross Corp:The フイブロネクチン・生理活性物質複合体の製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
JPH0611713B2 (ja) * 1983-04-08 1994-02-16 呉羽化学工業株式会社 ヒト免疫グロブリン結合抗腫瘍剤
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS60246400A (ja) * 1984-05-22 1985-12-06 Ajinomoto Co Inc アントラサイクリン系化合物及び制ガン剤
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
FR2577137B1 (fr) * 1985-02-13 1990-07-13 Sanofi Sa Glycoproteines antitumorales, modifiees sur leurs motifs glucidiques
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
FR2591894B1 (fr) * 1985-12-20 1988-04-01 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
FR2591895B1 (fr) * 1985-12-20 1988-08-26 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
FR2602683B1 (fr) * 1986-08-12 1990-03-30 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction
JPS62228025A (ja) * 1985-12-27 1987-10-06 Teijin Ltd 抗体複合体の製造方法
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US5004606A (en) * 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
EP0434765B1 (en) * 1988-09-30 1995-11-08 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US6225063B1 (en) 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
WO2006031614A2 (en) * 2004-09-10 2006-03-23 Tosk, Inc. Reduced toxicity methotrexate formulations and methods for using the same
NZ592293A (en) 2005-11-28 2012-10-26 Verrow Pharmaceuticals Inc Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
WO2009114325A2 (en) 2008-03-03 2009-09-17 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792298A1 (de) * 1968-08-16 1971-07-08 Rand Dev Corp Immunochromatographische Verteilung von loeslichen Antigenen
DE1814134A1 (de) * 1968-12-12 1970-09-10 Theurer Dr Med Karl Zusatzverfahren zur Herstellung von arzneimitteln mit selektivem Tropismus
AT340065B (de) * 1972-05-15 1977-11-25 Biological Developments Immunochemisches diagnostifizierverfahren zur prufung auf das vorliegen einer verbindung
DE2322552C2 (de) * 1972-11-06 1986-08-28 Pharmacia AB, Uppsala Verfahren zum Abtrennen von Protein A aus Staphylococcus aureus aus einer Flüssigkeit
DE2322533C2 (de) * 1972-11-06 1986-08-28 Pharmacia AB, Uppsala Verfahren zum Binden von Immunoglobulin und Hilfsmittel zur Durchführung des Verfahrens
FR2222083B1 (is) * 1973-03-22 1976-05-14 Fontaine Michel
US3966898A (en) * 1973-06-28 1976-06-29 Pharmacia Diagnostics Ab Method and reagent for determining immunologic materials
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions

Also Published As

Publication number Publication date
AU512255B2 (en) 1980-10-02
US4093607A (en) 1978-06-06
FR2312259B1 (is) 1978-10-20
JPH0133448B2 (is) 1989-07-13
SE7605942L (sv) 1976-11-28
AU1432176A (en) 1977-12-01
JPS51144723A (en) 1976-12-13
IL47372A0 (en) 1975-07-28
CA1064826A (en) 1979-10-23
DE2623736A1 (de) 1976-12-09
GB1523980A (en) 1978-09-06
FR2312259A1 (fr) 1976-12-24
ZA762966B (en) 1977-05-25
IL47372A (en) 1979-10-31
SE437767B (sv) 1985-03-18

Similar Documents

Publication Publication Date Title
CH619614A5 (is)
DE69434725T2 (de) Zell- und Serumproteinanker und Konjugate
DE69838953T2 (de) Methoden zur herstellung von glykosylierten antikörpern und antikörperfragmenten mit reaktiven ketongruppen
DE3781946T2 (de) Therapeutische oder radiodiagnostische substanz.
DE3783242T2 (de) Aminogruppen enthaltende hochmolekulare verbindungen und deren verwendung.
DE3685625T2 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
DE68912232T2 (de) Konjugate zytotoxischer Arzneimittel.
CH655010A5 (de) Pharmazeutischer wirkstoff mit antitumoraktivitaet.
DE2507901C2 (is)
DE69127334T2 (de) Verabreichung von Mitteln
DE2752694A1 (de) Verfahren zur gewinnung von immunglobulin zur intravenoesen verabreichung
DE2744983A1 (de) Mehrwertiger antigen-protein-komplex
DE69012747T2 (de) Polymyxinkonjugate.
DE3786832T2 (de) Verfahren zur Herstellung von Immunoglobulinzubereitungen für intravenöse Injektion.
DE69019959T2 (de) Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
DD201447A5 (de) Verfahren zur herstellung von als antikrebsmittel wirksamen immunoglobulin-konjugaten
DE4122210C2 (de) Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
DE2541931A1 (de) Immunologische verbindungen
DE3320560C2 (is)
DE194851T1 (de) Therapie der menschlichen tumore.
EP0810883A2 (de) Konjugat zur individuellen dosierung von arzneimitteln
DE3808166C2 (de) Immunglobulinkonjugate, Verfahren zu deren Herstellung sowie pharmazeutische Mittel, die diese enthalten
DE2853453A1 (de) Mittel zur therapie von immunkomplexerkrankungen
DE69815769T2 (de) Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms
DE69026387T2 (de) Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten

Legal Events

Date Code Title Description
PL Patent ceased